News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QR Pharma Release: Posiphen Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice


10/22/2012 9:42:17 AM

BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA. Alzheimer’s disease is a debilitating disease characterized pathologically by plaques and tangles in the brain. These deposits contain the toxic proteins Ab42 and phospho-Tau. Posiphen inhibits the synthesis of these two toxic proteins and reverses cognitive decline and synaptic dysfunction, making it a promising drug to treat neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.

Read at BioSpace.com


comments powered by Disqus
QR Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES